Pfizer (NYSE: PFE ) has been strategically increasing their business exposure in the oncology franchise by developing more cancer drugs to drive their future growth. I think the acquisition of Seagen could strengthen their Antibody-Drug Conjugate (ADC) technology. I am initiating with a 'Buy' rating withMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies s ...

The latest trading session saw Pfizer (PFE) ending at $28.97, denoting a +0.14% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.4%. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.6%.Shares of the drugmaker witnessed a gain of 0.63% over the previous month, beating the performance of the Medical sector with its loss of 2.27% and underperforming the S&P 500's gain of 1.71%.The investment community will be closely monitoring the performance of Pfi ...

Pfizer (PFE) announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved.Why PFE is Withdrawing the Drug All of a Sudden?This decision is based on the totality of clinical data, which shows that the benefit of the drug no longer outweighs the risks associated with its use. Per management, the data reflected an imbalance in vaso-occlusive crises (a common and painful complication of SCD) and fatal events tha ...

Key TakeawaysPfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns.The drug maker said the benefits of Oxbryta no longer outweigh the risks.The company's data indicated patients could suffer from severe pain and even death. Pfizer (PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in patients.  The company announced it was vo ...

CHINA - 2024/09/21: In this photo illustration, a Pfizer logo is displayed on the screen of a ... [+] smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesPfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years? Does this sound a bit ridiculous? Consider this – Pfizer stock was trading at levels of $54 per share just ab ...

High-Yield Dividend Stocks Overview - Passive income is a powerful tool for building long-term wealth, and high-yield dividend stocks provide steady cash flow without active management [1] - Success in dividend investing depends on identifying companies with attractive yields and strong financials to maintain or grow payouts over time [1] - Two stocks with yields above 5% are highlighted as compelling options for income-focused investors [1] Verizon Communications (VZ) - Verizon offers a 6.07% dividend yield and has an 18-year streak of consecutive dividend increases, recently raising its quarterly payout to 67.75 cents per share [2] - The company controls approximately 40% of the U.S. postpaid phone market share, enabling industry-leading margins and returns on capital [2] - Verizon's stock has risen over 18% year-to-date, benefiting from investor rotation into high-yield stocks ahead of anticipated interest rate cuts [2] - The company focuses on wireless service-revenue growth, adjusted EBITDA expansion, and free-cash-flow generation to support its dividend [3] - Shares trade at 9.5 times forward earnings, offering a margin of safety in case of a market pullback [3] Pfizer (PFE) - Pfizer provides a 5.69% dividend yield and has a portfolio of over 350 marketed medicines and 113 clinical-trial candidates, with a global presence in more than 200 countries [4] - The stock has declined over 50% from its three-year peak due to declining COVID-19 franchise sales, creating a potential value opportunity [4] - Pfizer trades at 9.6 times projected 2026 earnings, indicating a low valuation [4] - The company has a 15-year streak of consecutive dividend increases but faces concerns over its 436% payout ratio [5] - Management has committed to maintaining a top-tier dividend and implemented a $4 billion cost-saving initiative to strengthen its balance sheet [5] - Pfizer's future growth depends on its clinical pipeline, particularly potential blockbuster cancer treatments, which could improve its financial outlook [5] - The company's economically insensitive nature, high yield, and promising pipeline make it an attractive option for long-term income and stability [6]

Consider these three for a combination of dividend growth and a high yield.It will be over a decade before I start relying on dividend income from my stock portfolio. These days, I spend my time looking for businesses that pay juicy dividends, but it takes more than a high yield to get my attention.I like to invest in successful businesses that offer a high yield upfront and can grow their dividend payouts over time. These three stocks stand out because they offer ultra-high yields upfront and there's an ex ...

Group 1 - JR Research is recognized as a Top Analyst by TipRanks and Seeking Alpha for his expertise in Technology, Software, Internet, Growth, and GARP [1][2] - The investment strategy focuses on identifying attractive risk/reward opportunities with robust price action to generate alpha above the S&P 500 [1] - The approach combines price action analysis with fundamentals investing, avoiding overhyped stocks while targeting battered stocks with recovery potential [1] Group 2 - The investing group Ultimate Growth Investing specializes in identifying high-potential opportunities across various sectors with a focus on strong growth potential and contrarian plays [2] - The investment thesis typically has an 18 to 24 month outlook for realization [2] - The group aims to capitalize on growth stocks with robust fundamentals, buying momentum, and turnaround plays at attractive valuations [2]

Pfizer Inc. (PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic faded, the stock lost over 50% of its value from its all-time high. However, the company legacy goes far beyond this. With a long history of pioneering invention, the pharmaceutical giant has continually provided life-saving solutions in fields such as oncology and cardiovascular care. Further, it has been mak ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024Doses will be ready to ship to applicable European Union member states as soon as possible upon Euro ...